Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.

A live webcast of the Company’s presentation will be available under the “News & Events” tab in the Investor Calendar section of the Company’s website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 30 days following the event.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.

Media Contact:
Lia Dangelico
Deerfield Group
[email protected]

Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]

You May Also Be Interested In

• NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
• Holladay Distillery Helps Bring Made for KC Barbecue Championship to Weston
• Molina Healthcare of Michigan Donates $85,000 to Support Two Organizations Addressing Hunger and Housing in Bay and Saginaw Counties